Generic Drugs

The IGBA has introduced its first global intellectual property and competition report, addressing the urgent need to reform current regulations. But, in a bid to increase access to medicines across the world, did it stop short at just IP and patents?

US President Trump’s threat of a “25% or higher” import tariff on pharmaceuticals sends ripples through an already uncertain environment. With about half of generics sourced from India, captains of industry read between the lines

Generics Bulletin reviews the latest regulatory developments across the world.

While quarterly revenues show ups and downs in each region, Lupin is set on continued growth, with a touch of complexity and innovation – including shifting its thinking on the attractiveness of biosimilars.

The Polish player has won two grants sourced from the government’s National Recovery and Resilience Plan, which has given out $28.1m in funding in the latest round.

Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.

A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26.

Zydus’ latest results faced scrutiny from industry analysts due to a mixed performance where weaker revenue in the Indian company’s domestic market was offset by growth in the US. Meanwhile, the firm has just agreed a deal with Synthon for a 505(b)(2) hybrid product in the US.

At a lively AAM Access! conference in Florida, AAM President and CEO John Murphy acknowledged the negative effects of potential tariffs, but also suggested that the second Trump Administration could be an opportunity for the generics and biosimilars sectors to advance market reforms.

At a lively AAM Access! conference in Florida this week, the latest actions taken by Donald Trump ranked high on the agenda. But as well as acknowledging the negative effects of potential tariffs, the AAM’s president and CEO John Murphy also suggested that the advent of the second Trump administration could offer an opportunity for the generics and biosimilars sector to make its voice heard on proposed market reforms.